CKD-Associated Anemia: Pathophysiology, Diagnosis, and Treatment

1. Erythropoietin (EPO) Deficiency (Primary)

• Kidneys produce ~90% of EPO (peritubular fibroblasts in renal cortex)
• GFR <45 → ↓ EPO production → reduced RBC precursor stimulation
• Loss correlates with degree of renal fibrosis, not just GFR
• Board point: EPO levels are relatively low-normal or low in CKD anemia (inappropriate for degree of anemia)

2. Iron Deficiency (Common Complicating Factor)

• Absolute iron deficiency: Depleted body iron stores (TSAT <20%, ferritin <100 ng/mL)
  • Causes: GI blood loss, dialysis membrane loss, phlebotomy for labs
  • Enteral iron absorption impaired in CKD (uremia, phosphate binders)
• Functional iron deficiency: Adequate body iron but EPO resistance due to impaired iron mobilization
  • ESA therapy without concurrent iron repletion → worsening iron stores

3. Reduced RBC Lifespan (Moderate)

• Normal RBC lifespan: 120 days
• CKD RBC lifespan: 60-90 days (shortened by ~30-50%)
• Mechanisms: Uremic toxins, oxidative stress, altered RBC membrane
• Clinical significance: Even with normal EPO, RBC production cannot match increased turnover

4. Additional Contributing Factors

• Chronic inflammation: CRP, IL-6, TNF-α → hepcidin ↑ (blocks iron absorption)
• Nutritional deficiencies: B12, folate, copper
• Medications: ACE-I/ARB ↓ EPO; PPI ↓ iron absorption
• Comorbidities: Bleeding (GI ulcers, varices in liver disease), hemolysis

When to Screen for Anemia in CKD

• GFR <60 mL/min/1.73m² → annual screening
• GFR 30-59 → at least annual
• GFR <30 → every 3-6 months (higher risk)

Iron Status Assessment (Critical Before ESA Therapy)

Additional Labs

• CBC: Hemoglobin, MCV (microcytic if iron deficiency)
• Reticulocyte count: Should be elevated if EPO working; low reticulocyte count suggests inadequate EPO response or iron deficiency
• EPO level: Rarely needed; not used for dosing (many “normal” labs are inappropriately LOW for degree of anemia)
• B12, folate, copper: Screen if macrocytic anemia or neuropathy present
• Peripheral smear: Rule out hemolysis, schistocytes (HUS/TTP)

Oral Iron

• Preferred if GFR >45 and tolerated
• Formulations: Ferrous sulfate (FeSO₄) 325 mg daily = 65 mg elemental iron; ferrous gluconate (less GI upset)
• Dosing: 200-300 mg elemental iron daily
• Timing: On empty stomach for better absorption; separate from calcium binders (↓ absorption by 40%)
• Side effects: GI upset (~30%), constipation, black stools, adherence issues
• Expected response: ↑ Hb by 0.5-1 g/dL per month
• Pitfall: Enteric-coated formulations bypass absorption site; avoid

Intravenous Iron (Preferred in Dialysis; Consider if Oral Fails)

Advantages: Bypasses GI barrier, doesn’t require gastric acid, rapid iron repletion

Formulations (equivalent iron content, different pharmacokinetics): - Ferric carboxymaltose (FCM) — 750 mg IV infusion over 15 min; can repeat weekly - Single-dose equivalent: Up to 750 mg = 14 mg/kg maximum - Preferred in CKD (no anaphylaxis in clinical trials) - Iron sucrose (older standard) — 100-200 mg IV × 10 doses - Must give in divided doses; slower repletion - Ferumoxytol — 510 mg IV over 17 min, repeat 3-4 days later - Rapid repletion but more CYP450 interactions

Dosing algorithm: 1. Calculate iron deficit: Weight (kg) × (15 - Hb in g/dL) × 2.4 + 500 mg (storage deficit) 2. Baseline: Check TSAT, ferritin, Hb 3. Recheck in 2-4 weeks: Assess Hb response and repeat iron studies 4. Maintenance: Some CKD patients need IV iron q 3-6 months if ongoing losses

Adverse effects: Transient hypophosphatemia (FCM), arthralgias/myalgias (transient), rare anaphylaxis (mostly iron dextran; <1% with modern formulations)

Pathophysiology of ESA Action

• Recombinant EPO (epoetin alfa/beta) or long-acting darbepoetin alfa
• Binds EPO receptor on erythroid progenitors → ↑ proliferation, maturation
• Requires adequate iron, B12, folate

Indications for ESA Initiation

• Hb 9.0-10.5 g/dL in CKD with symptoms OR
• Hb <9.0 g/dL regardless of symptoms
• ≥4-6 weeks of stable iron therapy with documented response before escalating ESA dose

ESA Agents & Dosing

Dosing principles: - Start low: ESA-naive patients 25-50 U/kg IV 2-3× weekly - Titrate: Increase by 25-50 U/kg every 2-4 weeks if Hb rising slowly - Ceiling: Most patients reach goal at 200-300 U/kg/week - Maintenance: Once Hb at goal, find minimum dose to maintain 10-11.5 g/dL

Target Hemoglobin & Cardiovascular Safety

• TREAT Trial (2009): Darbepoetin to Hb approximately 13 g/dL vs placebo (rescue darbepoetin only if Hb <9) in T2DM + non-dialysis CKD → NO reduction in death/CV events or death/ESRD; stroke nearly doubled (HR 1.92, 95% CI 1.38–2.68) [1]
• CHOIR Trial (2006): Epoetin alfa to Hb 13.5 vs 11.3 g/dL → ↑ composite of death, MI, HF hospitalization, and stroke (HR 1.34, 95% CI 1.03–1.74) [2]
• Current guideline recommendation: Target Hb 10-11.5 g/dL (KDIGO 2021)
  • Rationale: Balances symptom improvement with minimizing CV risk
  • Do NOT target Hb >12 g/dL (↑ thrombosis, hypertension)
  • Do NOT allow Hb to fall <9 g/dL if preventable

Mechanism

• Blocks degradation of HIF (hypoxia-inducible factor) → ↑ endogenous EPO production
• Also ↑ hepcidin (promotes iron absorption), ↑ vascular endothelial growth factor (VEGF)
• Oral agents: roxadustat, daprodustat, vadadustat

Agents & Evidence

• Roxadustat: Oral, dosed 3× weekly. Approved outside the US (including China and Japan); not FDA-approved in the United States
• Daprodustat: Oral, once daily. FDA-approved (2023) for anemia of CKD in adults on dialysis
• Vadadustat: Oral, once daily. FDA-approved (2024) for anemia of CKD in adults on dialysis
  • INNO2VATE (dialysis-dependent CKD): non-inferior to darbepoetin alfa for MACE (HR 0.96, 95% CI 0.83–1.11) and for Hb correction/maintenance [3]
  • PRO2TECT (non–dialysis-dependent CKD): met the Hb non-inferiority margin but did NOT meet the cardiovascular non-inferiority margin (MACE HR 1.17, 95% CI 1.01–1.36) [4]
• Class advantage: oral dosing; ↓ hepcidin may improve iron availability
• Class caution: cardiovascular safety is not uniform across agents or across dialysis status — do not assume a class effect

When to Use HIF-PHI vs ESA

• Preferred if: Patient refusal of injections, poor IV access, ESA hyporesponsiveness
• Not preferred if: Acute anemia requiring rapid Hb correction (ESA faster)
• Monitoring: Similar to ESA (Hb target 10-11.5); check BP, ferritin, transferrin saturation

Step 1: Confirm Iron Sufficiency

• Ferritin <100 ng/mL OR TSAT <20% → Give oral iron (or IV if GI intolerance)
• Wait 4-6 weeks for response before escalating ESA dose
• Recheck ferritin and TSAT before starting ESA

Step 2: Initiate ESA or HIF-PHI

• ESA: Start low (50 U/kg IV 2-3× weekly) if Hb 9-10.5 and symptomatic
• HIF-PHI: Consider if patient preference or ESA contraindication
• Set Hb target: 10-11.5 g/dL

Step 3: Titrate Dose

• Increase ESA by 25-50 U/kg every 2-4 weeks if Hb rising <1 g/dL per month
• Recheck ferritin and reticulocyte count monthly
• If Hb >11.5 g/dL, reduce ESA dose by 25%

Step 4: Monitor for Hyporesponsiveness

• If requiring >300 U/kg/week ESA despite adequate iron: Investigate
• Consider: Blood loss, inflammation (CRP), hemolysis (haptoglobin, LDH), malignancy, infection, copper deficiency

Step 5: Transition to Dialysis or Transplant

• Dialysis: Continue IV iron + ESA with adjusted dosing
• Renal transplant: Taper ESA immediately post-transplant (graft produces EPO); anemia usually resolves within 2-3 months